Bdenza OS Oral Solution

Introduction

Bdenza OS is a prescription medication that contains the active ingredient Enzalutamide. It is available under the brand name Bdenza OS. This medication is primarily used in the treatment of prostate cancer.

Uses

Bdenza OS is prescribed to adult men with advanced prostate cancer. It is specifically used in the treatment of metastatic castration-resistant prostate cancer (mCRPC), where the cancer has spread to other parts of the body and continues to grow despite hormonal therapy.

Dosage and Administration

The recommended dosage of Bdenza OS is four 40 mg capsules taken orally once daily. Follow your healthcare provider’s instructions regarding the dosage and duration of treatment. The capsules should be swallowed whole with water, and can be taken with or without food.

Mechanism of Action

The active ingredient Enzalutamide in Bdenza OS belongs to a class of medications known as androgen receptor inhibitors. It works by blocking the effects of androgens (male hormones) in the body, which play a role in the growth and spread of prostate cancer cells. By inhibiting the androgen receptor, Enzalutamide helps to slow down the progression of the cancer and improve patient outcomes.

Side Effects

Common side effects may include fatigue, loss of appetite, constipation, diarrhea, and hot flashes. Note that not all patients will experience these side effects, and the severity may vary from person to person.

Serious side effects are rare but can occur. If you experience any of the following, seek immediate medical attention:

• Severe allergic reaction (e.g., rash, itching, swelling, severe dizziness)
• Chest pain or shortness of breath
• Bone fractures or pain
• Seizures or changes in mood or behavior

Drug Interactions

Bdenza OS may interact with other medications, which can affect how it works or increase the risk of side effects. Inform your healthcare provider about all the medications you are currently taking, including prescription, over-the-counter, and herbal products. Some common drug interactions include:

• Strong CYP2C8 inhibitors (e.g., gemfibrozil) may increase the levels of Bdenza OS in the body, potentially increasing the risk of side effects.
• Strong CYP3A4 inducers (e.g., rifampin) may decrease the levels of Bdenza OS in the body, reducing its effectiveness.

Precautions

Before starting treatment with Bdenza OS, discuss any medical conditions or allergies you have with your healthcare provider. Additionally, let your healthcare provider know about all the medications you are currently taking to avoid any potential interactions.

Bdenza OS is not recommended for use in women or children. It should only be used by adult men with prostate cancer under the supervision of a healthcare professional.

Storage

Bdenza OS should be stored at room temperature (between 20°C and 25°C or 68°F and 77°F). Keep the medication in its original container and protect it from moisture and light. Do not store it in the bathroom or near the kitchen sink.

Patient Tips

• Take the medication exactly as prescribed by your healthcare provider. Do not adjust the dosage or stop taking it without consulting your healthcare provider.
• attend all scheduled appointments with your healthcare provider for regular check-ups and monitoring of your condition.
• If you experience any new or worsening symptoms, or have any concerns or questions about your treatment, contact your healthcare provider.
• It may take some time for Bdenza OS to show its full effect. Be patient and continue taking the medication as directed.
• Remember to store the medication properly and keep it out of reach of children and pets.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Enzalutamide (Drugs.com) [Accessed 11 Jun. 2024] (online) Available at:
• enzalutamide capsule (RX) [Accessed 18 Jun. 2024] (online) Available at:
• Enzalutamide (MedlinePlus) [Accessed 19 Jun. 2024] (online) Available at:
• Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019 Nov 10;37(32):2974-2986. doi: 10.1200/JCO.19.00799. Epub 2019 Jul 22. [Accessed 29 Jun. 2024] Available at: